Pfizer stock gains 1.98 percent on October 7

Published on 10/07/2026 at 16:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock carries second-quarter revenue of USD 15.03 billion and adjusted EPS of USD 0.77 on October 7. A 21-analyst consensus sets a USD 28.39 average target.

Dokumentarische Schwarzweiß-Aufnahme eines Pharma-Labors, Symbolbild für Pfizer Inc — Schwarzweiß-Reportagefoto aus einem Forschungslabor illustriert Pfizer Inc. mit ISIN US7170811035 im Pharma-Sektor, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) was trading at USD 28.05 on NYSE at 10:57 a.m. ET on October 7, 2026, up 1.98 percent from USD 27.50. The session puts the pharmaceutical company's share price within its USD 23.62 to USD 29.21 52-week range, with the upper boundary 4.14 percent away.

Quarterly figures set the baseline

Vermögenszentrum reported on October 5, 2026, that Pfizer's second-quarter 2026 revenue was USD 15.03 billion and adjusted diluted EPS was USD 0.77. The same report said management lifted full-year 2026 revenue guidance to USD 60.5 billion-USD 62.5 billion while reaffirming adjusted EPS guidance of USD 2.80-USD 3.00.

The Q2 revenue figure exceeded the consensus estimate of USD 14.40 billion by USD 0.63 billion, while adjusted EPS surpassed the USD 0.68 estimate by USD 0.09, according to MarketBeat on September 20, 2026. That comparison gives the quarterly release more weight than the daily price move alone.

Analysts see limited upside

MarketBeat reported that 21 analysts give Pfizer a consensus Hold rating, with 14 Holds, four Buys, two Sells and one Strong Buy. The average 12-month target is USD 28.39, which lies 1.2 percent above the USD 28.05 trading price.

On October 6, 2026, Markets Insider reported that Scotiabank raised its Pfizer target from USD 30.00 to USD 33.00 while keeping an Outperform rating. The new target stands 17.7 percent above the October 7 trading price, a wider gap than the broader analyst average.

November 3 is the next checkpoint

Pfizer scheduled its third-quarter 2026 results and analyst webcast for November 3, 2026, at 10:00 a.m. ET. That date will test whether non-COVID demand can sustain the revenue guidance range after the second-quarter earnings beat.

Pfizer stock stays below its yearly high

Pfizer stock was last at USD 28.05 on NYSE on October 7, 2026, at 10:57 a.m. ET. Its market capitalization was USD 159.8 billion and trading volume was 5,971,329 shares at that timestamp.